ARTEL and IonGate Join Forces to Advance Drug Discovery Research in North America
News Jun 25, 2008
ARTEL and IonGate Biosciences announced their strategic partnership to support the growing application of IonGate’s drug discovery technology. The German biotechnology company will leverage ARTEL’s local infrastructure, customer relationships and market knowledge to increase the exposure and use of its discovery systems and assay development services in North America.
The partnership will focus on IonGate’s SURFE2R Technology, which enables effective research involving drug targets such as membrane transporters and ligand-gated ion channels.
Membrane transport proteins play an important role in numerous biological functions, and have been linked to cardiac, neurologic and metabolic disorders, yet they represent a relatively unexplored segment of the drug discovery market. The previous lack of technology for efficient transporter screening has led pharmaceutical companies to focus the majority of their research initiatives on other targets.
Ligand-gated ion channel proteins, while more frequently targeted, typically are also subject to less-than-optimal screening methods. IonGate’s SURFE2R (SURFace Electrogenic Event Reader) Technology represents a significant advance toward more efficient screening of transporters as well as ligand-gated ion channels.
“Transporter-focused drug discovery initiatives are poised for rapid growth worldwide, and the U.S. demand for our SURFE2R Technology is rising,” said Dr. Thiemo Gropp Ph.D., Managing Director, IonGate Biosciences GmbH. “With ARTEL’s support and market expertise, we will be able to deliver the same personalized support to our customers in North America as we deliver to our customers in Europe.”
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
New Drug Compounds Help Prevent Hearing LossNews
Researchers from St. Jude Children's Research Hospital have discovered that inhibiting an enzyme called cyclin-dependent kinase 2 (CDK2) protects mice and rats from noise- or drug-induced hearing loss. The study suggests that CDK2 inhibitors prevent the death of inner ear cells, which has the potential to save the hearing of millions of people around the world.READ MORE
Empowering Women in Technology Key to Boosting UK EconomyNews
A new report launched at London Stock Exchange for International Women’s Day, reveals the critical role women play in driving economic growth across the UK, with detailed research on 1,279 women-led companies showing a total contribution of £25.9 billion in revenue to the UK economy.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018